PCN181 Real-World Evidence (RWE) in Reimbursement, Pricing, and Health Technology Assessment (HTA) in ASIA. How CAN Rwe Supplement Trial DATA in Oncology Indications in a Premarketing Setting?
| Autor: | Schoenherr, N., Brogan, A., Outteridge, G.J., Patel, J., Perez, Zaballos MT, Bobiak, S. |
|---|---|
| Zdroj: | In Value in Health June 2021 24 Supplement 1:S52-S53 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect